ISTH 2026
-

Hemab Therapeutics Reports Positive Sutacimig Data for Coagulation Disorders at ISTH 2026
Hemab Therapeutics presented positive Phase 2 long-term extension data for its sutacimig treatment, showing significant bleed reduction in coagulation disorder patients.
